Quantitative Ultrasound of the Calcaneus (QUS): A Valuable Tool in the Identification of Patients with Non-metastatic Prostate Cancer Requiring Screening for Osteoporosis

Overview

Journal Bone Rep

Date 2023 Jul 10

PMID 37425192

Authors

B B Nieuwkamer

J P M Vrouwe

P M Willemse

M P J Nicolai

R F M Bevers

R C M Pelger

N A T Hamdy

S Osanto

Affiliations

Soon will be listed here.

Abstract

Summary: Osteoporosis and associated increased fracture risk are common in non-metastatic prostate carcinoma, mainly due to androgen deprivation therapy, but these often remain underdiagnosed and untreated. We demonstrate that QUS is a safe, less costly pre-screen tool that reduces by up to two-third the number of patients requiring referral for DXA for osteoporosis screening.

References

Schuit S, van der Klift M, Weel A, de Laet C, Burger H, Seeman E . Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004; 34(1):195-202. DOI: 10.1016/j.bone.2003.10.001. View

Kanis J, Bianchi G, Bilezikian J, Kaufman J, Khosla S, Orwoll E . Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int. 2011; 22(11):2789-98. PMC: 3555694. DOI: 10.1007/s00198-011-1632-z. View

Nayak S, Roberts M, Greenspan S . Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med. 2011; 155(11):751-61. PMC: 3318923. DOI: 10.7326/0003-4819-155-11-201112060-00007. View

Cornford P, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch M, De Santis M . EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2020; 79(2):263-282. DOI: 10.1016/j.eururo.2020.09.046. View

Johnell O, Kanis J, Oden A, Johansson H, De Laet C, Delmas P . Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005; 20(7):1185-94. DOI: 10.1359/JBMR.050304. View

Binkley N, Adler R, Bilezikian J . Osteoporosis diagnosis in men: the T-score controversy revisited. Curr Osteoporos Rep. 2014; 12(4):403-9. PMC: 4275049. DOI: 10.1007/s11914-014-0242-z. View

Saylor P, Rumble R, Michalski J . Bone Health and Bone-Targeted Therapies for Prostate Cancer: American Society of Clinical Oncology Endorsement Summary of a Cancer Care Ontario Guideline. JCO Oncol Pract. 2020; 16(7):389-393. DOI: 10.1200/JOP.19.00778. View

Coleman R, Body J, Aapro M, Hadji P, Herrstedt J . Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014; 25 Suppl 3:iii124-37. DOI: 10.1093/annonc/mdu103. View

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V . EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011; 59(4):572-83. DOI: 10.1016/j.eururo.2011.01.025. View

10.

Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J . Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations.... Arch Osteoporos. 2013; 8:136. PMC: 3880487. DOI: 10.1007/s11657-013-0136-1. View

11.

Gluer C, Eastell R, Reid D, Felsenberg D, Roux C, Barkmann R . Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. J Bone Miner Res. 2004; 19(5):782-93. DOI: 10.1359/JBMR.040304. View

12.

Njeh C, Hans D, Li J, Fan B, Fuerst T, He Y . Comparison of six calcaneal quantitative ultrasound devices: precision and hip fracture discrimination. Osteoporos Int. 2001; 11(12):1051-62. DOI: 10.1007/s001980070027. View

13.

Moayyeri A, Kaptoge S, Dalzell N, Bingham S, Luben R, Wareham N . Is QUS or DXA better for predicting the 10-year absolute risk of fracture?. J Bone Miner Res. 2009; 24(7):1319-25. DOI: 10.1359/jbmr.090212. View

14.

Smith M, Boyce S, Moyneur E, Duh M, Raut M, Brandman J . Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006; 175(1):136-9. DOI: 10.1016/S0022-5347(05)00033-9. View

15.

Greenspan S, Coates P, Sereika S, Nelson J, Trump D, Resnick N . Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005; 90(12):6410-7. DOI: 10.1210/jc.2005-0183. View

16.

Heidenreich A, Witjes W, Bjerklund-Johansen T, Patel A . Therapies used in prostate cancer patients by European urologists: data on indication with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonates. Urol Int. 2012; 89(1):30-8. DOI: 10.1159/000338810. View

17.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

18.

van Casteren-Messidoro C, Huisman A, Birnie E, van Gelder M, van de Geijn F, Hamberg P . Quantitative ultrasound of the heel as triage test to measure bone mineral density compared with dual energy X-ray absorptiometry in men with prostate cancer commencing with androgen deprivation therapy. Neth J Med. 2015; 72(10):528-32. View

19.

Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G . Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(9):1119-1134. DOI: 10.1016/j.annonc.2020.06.011. View

20.

Hans D, Baim S . Quantitative Ultrasound (QUS) in the Management of Osteoporosis and Assessment of Fracture Risk. J Clin Densitom. 2017; 20(3):322-333. DOI: 10.1016/j.jocd.2017.06.018. View